Literature DB >> 33115373

Predictors of the start of declining eGFR in patients with systemic lupus erythematosus.

Terry Cheuk-Fung Yip1, Suchi Saria2,3,4, Michelle Petri5, Laurence S Magder6.   

Abstract

OBJECTIVE: To characterize the longitudinal trajectory of estimated glomerular filtration rate (eGFR) in patients with systemic lupus erythematosus (SLE) and identify predictors of the change in eGFR trajectory.
METHODS: The longitudinal eGFR levels of patients in the Hopkins Lupus Cohort were modelled by piecewise linear regression to evaluate the slope of different line segments. The slopes were classified into declining (≤-4 mL/min/1.73 m2 per year), stable (-4 to 4 mL/min/1.73 m2 per year), and increasing (≥4 mL/min/1.73 m2 per year) states. The transition rate between states and the impact of clinical parameters were estimated by a Markov model.
RESULTS: The analysis was based on 494 SLE patients. At a mean follow-up of 8.8 years, 347 (70.2%), 107 (21.7%), 33 (6.7%), and 7 (1.4%) patients had zero, one, two, and three state transitions, respectively. In patients with no transition, 37 (10.7%), 308 (88.8%), and 2 (0.6%) were in declining, stable, and increasing state, respectively. In patients with one transition, 43 (40.2%) changed from declining to stable state while 29 (27.1%) changed from stable to declining state. When patients were in a non-declining GFR state, those who were younger and African Americans were more likely to transition to a declining GFR state. In adjusted analyses, high blood pressure, C4 and low hematocrit were associated with change from non-declining to declining state. High urine protein-to-creatinine ratio also tended to be associated with change from non-declining to declining state. African American patients were less likely to move from declining to non-declining state. Use of prednisone was associated with change from declining to non-declining state.
CONCLUSIONS: Patients with high blood pressure, low complement C4, low haematocrit, and high urine protein-to-creatinine ratio are more likely to have a declining eGFR trajectory, while the use of prednisone stabilizes the declining eGFR trajectory.

Entities:  

Keywords:  Epidemiology; glomerular filtration rate; longitudinal; renal lupus; systemic lupus erythematosus

Year:  2020        PMID: 33115373      PMCID: PMC7770013          DOI: 10.1177/0961203320966393

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  24 in total

Review 1.  Lupus nephritis.

Authors:  J S Cameron
Journal:  J Am Soc Nephrol       Date:  1999-02       Impact factor: 10.121

Review 2.  Exploring complement activation to develop biomarkers for systemic lupus erythematosus.

Authors:  George C Tsokos
Journal:  Arthritis Rheum       Date:  2004-11

3.  A decrease in complement is associated with increased renal and hematologic activity in patients with systemic lupus erythematosus.

Authors:  A Ho; S G Barr; L S Magder; M Petri
Journal:  Arthritis Rheum       Date:  2001-10

4.  American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis.

Authors:  Bevra H Hahn; Maureen A McMahon; Alan Wilkinson; W Dean Wallace; David I Daikh; John D Fitzgerald; George A Karpouzas; Joan T Merrill; Daniel J Wallace; Jinoos Yazdany; Rosalind Ramsey-Goldman; Karandeep Singh; Mazdak Khalighi; Soo-In Choi; Maneesh Gogia; Suzanne Kafaja; Mohammad Kamgar; Christine Lau; William J Martin; Sefali Parikh; Justin Peng; Anjay Rastogi; Weiling Chen; Jennifer M Grossman
Journal:  Arthritis Care Res (Hoboken)       Date:  2012-06       Impact factor: 4.794

5.  Trends in the incidence, demographics, and outcomes of end-stage renal disease due to lupus nephritis in the US from 1995 to 2006.

Authors:  Karen H Costenbader; Amrita Desai; Graciela S Alarcón; Linda T Hiraki; Tamara Shaykevich; M Alan Brookhart; Elena Massarotti; Bing Lu; Daniel H Solomon; Wolfgang C Winkelmayer
Journal:  Arthritis Rheum       Date:  2011-06

6.  European genetic ancestry is associated with a decreased risk of lupus nephritis.

Authors:  Ilana B Richman; Kimberly E Taylor; Sharon A Chung; Laura Trupin; Michelle Petri; Edward Yelin; Robert R Graham; Annette Lee; Timothy W Behrens; Peter K Gregersen; Michael F Seldin; Lindsey A Criswell
Journal:  Arthritis Rheum       Date:  2012-10

7.  Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus.

Authors:  Michelle Petri; Ana-Maria Orbai; Graciela S Alarcón; Caroline Gordon; Joan T Merrill; Paul R Fortin; Ian N Bruce; David Isenberg; Daniel J Wallace; Ola Nived; Gunnar Sturfelt; Rosalind Ramsey-Goldman; Sang-Cheol Bae; John G Hanly; Jorge Sánchez-Guerrero; Ann Clarke; Cynthia Aranow; Susan Manzi; Murray Urowitz; Dafna Gladman; Kenneth Kalunian; Melissa Costner; Victoria P Werth; Asad Zoma; Sasha Bernatsky; Guillermo Ruiz-Irastorza; Munther A Khamashta; Soren Jacobsen; Jill P Buyon; Peter Maddison; Mary Anne Dooley; Ronald F van Vollenhoven; Ellen Ginzler; Thomas Stoll; Christine Peschken; Joseph L Jorizzo; Jeffrey P Callen; S Sam Lim; Barri J Fessler; Murat Inanc; Diane L Kamen; Anisur Rahman; Kristjan Steinsson; Andrew G Franks; Lisa Sigler; Suhail Hameed; Hong Fang; Ngoc Pham; Robin Brey; Michael H Weisman; Gerald McGwin; Laurence S Magder
Journal:  Arthritis Rheum       Date:  2012-08

8.  The significance of serial measurements of serum complement C3 and C4 components and DNA binding capacity in patients with lupus nephritis.

Authors:  E H Garin; W H Donnelly; S T Shulman; R Fernandez; C Finton; R L Williams; G A Richard
Journal:  Clin Nephrol       Date:  1979-10       Impact factor: 0.975

Review 9.  Update on Lupus Nephritis.

Authors:  Salem Almaani; Alexa Meara; Brad H Rovin
Journal:  Clin J Am Soc Nephrol       Date:  2016-11-07       Impact factor: 8.237

10.  A Longitudinal Analysis of Outcomes of Lupus Nephritis in an International Inception Cohort Using a Multistate Model Approach.

Authors:  John G Hanly; Li Su; Murray B Urowitz; Juanita Romero-Diaz; Caroline Gordon; Sang-Cheol Bae; Sasha Bernatsky; Ann E Clarke; Daniel J Wallace; Joan T Merrill; David A Isenberg; Anisur Rahman; Ellen M Ginzler; Michelle Petri; Ian N Bruce; M A Dooley; Paul Fortin; Dafna D Gladman; Jorge Sanchez-Guerrero; Kristjan Steinsson; Rosalind Ramsey-Goldman; Munther A Khamashta; Cynthia Aranow; Graciela S Alarcón; Barri J Fessler; Susan Manzi; Ola Nived; Gunnar K Sturfelt; Asad A Zoma; Ronald F van Vollenhoven; Manuel Ramos-Casals; Guillermo Ruiz-Irastorza; S Sam Lim; Kenneth C Kalunian; Murat Inanc; Diane L Kamen; Christine A Peschken; Soren Jacobsen; Anca Askanase; Chris Theriault; Vernon Farewell
Journal:  Arthritis Rheumatol       Date:  2016-08       Impact factor: 10.995

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.